Biohaven .(BHVN) - 2025 Q4 - Annual Results

Clinical Development - Biohaven's BHV-1300 achieved up to an 87% reduction in IgG levels in healthy volunteers, with a pivotal study planned for Graves' disease in H2 2026[1] - BHV-1400 demonstrated a mean reduction of over 60% in Gd-IgA1 levels within hours, with a pivotal study set to begin in Q1 2026[1] - In an ongoing study, 75 mg of opakalim resulted in ≥50% reductions in seizure frequency for the majority of participants after at least six months, with pivotal results expected in H2 2026[1] - Taldefgrobep alfa, targeting obesity, is currently in a Phase 2 study with topline results expected in H2 2026[1] - Biohaven's next-generation antibody drug conjugate, BHV-1510, continues to show clinical activity in various cancers with a differentiated safety profile[2] - BHV-1510 demonstrated a confirmed objective response rate of 60% in non-small cell lung cancer (NSCLC) and 100% in endometrial cancer during the Phase 1 study[23] - Taldefgrobep showed significant reductions in total body fat mass (>6%) and increases in lean muscle mass (up to 4%) after one month of dosing in a Phase 1 study[22] - The company initiated a Phase 2 proof-of-concept study for taldefgrobep in obesity in Q4 2025, with topline results expected in the second half of 2026[22] - BHV-1400 pivotal study design was aligned with the FDA, with study initiation expected in Q1 2026[30] Financial Performance - Biohaven's cash and equivalents totaled approximately $322 million as of December 31, 2025, with an additional $178.9 million raised from the sale of 17.2 million common shares[5] - The company reported gross proceeds of approximately $200 million from a public offering in November 2025[11] - The net loss for Q4 2025 was $145.6 million, or $1.21 per share, compared to a net loss of $186.8 million, or $1.85 per share, in Q4 2024[33] - Full year 2025 R&D expenses totaled $635.1 million, down from $795.9 million in 2024, largely due to a one-time non-cash expense in 2024[34] - The company reported a net loss attributable to common shareholders of $738.8 million, or $6.86 per share, for the year ended December 31, 2025, compared to $846.4 million, or $9.28 per share, in 2024[37] - Cash, cash equivalents, and marketable securities totaled approximately $322.0 million as of December 31, 2025, with an additional $178.9 million raised from the issuance of 17.2 million common shares[27] - General and Administrative (G&A) expenses for Q4 2025 were $20.8 million, a decrease from $22.5 million in Q4 2024, primarily due to reduced personnel costs[31] - Research and Development (R&D) expenses for Q4 2025 were $121.9 million, a decrease of $45.5 million from $167.5 million in Q4 2024, primarily due to reduced program spending[28] - Total operating expenses for the year ended December 31, 2025, were $745,378,000, down from $885,111,000 in 2024, reflecting a reduction of approximately 16%[44] - The net loss for Q4 2025 was $145,555,000, compared to a net loss of $186,843,000 in Q4 2024, indicating an improvement of about 22%[44] - Cash and cash equivalents increased to $229,957,000 as of December 31, 2025, from $99,134,000 as of December 31, 2024, showing a significant increase of approximately 132%[46] - Total assets decreased to $451,447,000 as of December 31, 2025, down from $615,107,000 in 2024, a decline of about 27%[46] - The accumulated deficit increased to $2,084,536,000 as of December 31, 2025, compared to $1,345,714,000 in 2024, reflecting an increase of approximately 55%[46] - Non-GAAP adjusted net loss for Q4 2025 was $107,903,000, compared to $173,258,000 in Q4 2024, a reduction of about 38%[49] - Non-GAAP adjusted net loss per share for the year ended December 31, 2025, was $5.55, down from $8.67 in 2024, indicating an improvement of approximately 36%[49] Strategic Initiatives - The company initiated strategic cost optimization measures in Q4 2025, aiming for a 60% reduction in annual direct R&D spend[11] - Biohaven entered a memorandum of understanding with KAUST in January 2026 to enhance next-generation degrader development[8] - The company is exploring strategic partnerships to advance its broader degrader portfolio targeting high-value immune-mediated diseases[1] - Biohaven plans to continue its focus on clinical trials and regulatory filings, with an emphasis on reducing annual direct R&D spending[42]